TABLE III.
Characteristics of women diagnosed with breast cancer, screening rounds, and tumour pathologic and prognostic factors
| Patient | Age (years) | Previous breast cancer | Genetic status | Breast densitya | Screening rounds (n) | Clinical breast exam | Mammography | Ultrasonography | Magnetic resonance imaging | Tumour size (cm) | T stage |
Histologic |
Status |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type | Grade | Nodal | her2/neu | er | ||||||||||||
| Invasive | ||||||||||||||||
| 1 | 51 | Contralateral | Tested negative | 3 | 1 | − | + | + | + | 1.5 | T1c | idc | 1/3 | − | − | + |
| 2 | 54 | None | BRCA1 | 2 | 1 | + | + | + | + | 1.2 | T1c | idc | 2/3 | − | − | − |
| 3 | 53 | Ipsilateral | BRCA2 | 3 | 1 | − | + | + | − | 1.6 | T1c | idc | 2/3 | np | − | + |
| 4 | 47 | Contralateral | BRCA1 | 3 | 2 | − | − | − | + | 2.0 | T1c | idc | 3/3 | − | − | − |
| 5 | 46 | None | BRCA2 | 4 | 2 | − | − | − | + | 1.1 | T1c | idc | 2/3 | − | − | + |
| 6 | 35 | Contralateral | BRCA1 | 3 | 2 | + | + | + | + | 3.4 | T2 | idc | 3/3 | − | − | − |
| 7 | 41 | None | BRCA2 | 2 | 2 | − | + | − | + | 0.6 | T1a | idc | 1/3 | − | − | + |
| 8 | 42 | None | BRCA1 | 3 | 2 | − | − | + | + | 6.0 | T3 | ilc | 2/3 | 2/6 | − | + |
| 9 | 45 | Contralateral | BRCA1 | 3 | 3 | − | − | − | + | 0.6 | T1b | idc | 2/3 | − | − | + |
| In situ | ||||||||||||||||
| 10 | 28 | Contralateral | BRCA1 | 4 | 2 | − | + | − | − | 1.1 | Tis | dcis | 3/3 | − | np | − |
| 11 | 48 | Contralateral and ipsilateral | BRCA2 | 3 | 2 | − | − | − | + | 0.5 | Tis | dcis | 3/3 | np | np | + |
| 12 | 44 | Contralateral | BRCA2 | 4 | 3 | − | + | + | + | 0.4 | Tis | dcis | 3/3 | np | np | + |
a
1 = predominantly fatty; 2 = scattered fibroglandular densities; 3 = heterogeneously dense; 4 = extremely dense.
her2/neu = human epidermal growth factor receptor 2; er = estrogen receptor; idc = infiltrating ductal carcinoma; ilc = infiltrating lobular carcinoma; dcis = ductal carcinoma in situ; np = not performed.